throbber
Trials@uspto.gov
`Tel: 571-272-7822
`
`
`
`
`Paper 12
` Entered: January 3, 2017
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________
`
`MERCK SHARP & DOHME CORP.,
`Petitioner,
`
`v.
`
`GENENTECH, INC. AND CITY OF HOPE,
`Patent Owner.
`_______________
`
`Case IPR2017-00047
`Patent 6,331,415 B1
`_______________
`
`Before TONI R. SCHEINER, LORA M. GREEN, and
`SUSAN L. C. MITCHELL, Administrative Patent Judges.
`
`GREEN, Administrative Patent Judge.
`
`
`DECISION
`
`Institution of Inter Partes Review and Grant of Motion for Joinder
`37 C.F.R. § 42.108
`37 C.F.R. § 42.122(b)
`
`
`
`
`
`
`

`

`IPR2017-00047
`Patent No. 6,331,415 B1
`
`I.
`
`INTRODUCTION
`Merck Sharp & Dohme Corp. (“Petitioner” or “Merck”) filed a
`Petition (Paper 2, “Pet.”) requesting an inter partes review of claims 1–4,
`11, 12, 14, 18–20, and 33 of U.S. Patent No. 6,331,415 B1 (Ex. 1001, “the
`’415 patent”). Petitioner filed also a Motion for Joinder (Paper 3, “Mot.”).
`The Motion for Joinder seeks to join this proceeding with Mylan
`Pharmaceuticals, Inc. v. Genentech, Inc. and City of Hope, Case IPR2016-
`00710 (“the ’710 IPR”). Mot. 1. Genentech Inc. and City of Hope
`(collectively, “Patent Owner” or “Genentech”) filed a Response to
`Petitioner’s Motion for Joinder. Paper 10.
`For the reasons explained below, we institute an inter partes review of
`challenged claims 1–4, 11, 12, 14, 18–20, and 33, and grant Petitioner’s
`Motion for Joinder.
`
`II.
`
`INSTITUTION OF INTER PARTES REVIEW
`The Petition in this proceeding asserts the same grounds as those on
`which we instituted review in the ’710 IPR. Specifically, based on the
`Petition filed by Mylan Pharmaceuticals, Inc. (“Mylan”), on March 3, 2016,
`we instituted a trial in the ’710 IPR on the following grounds:
`References
`Basis
`Claims Challenged
`Bujard1 and Riggs & Itakura2
`§ 103(a)
`1, 3, 4, 11, 12, 14,
`
`19, and 33
`
`
`1 Bujard et al., US 4,495,280, issued Jan. 22, 1985 (“Bujard”) (Ex. 1002).
`2 Arthur D. Riggs and Keiichi Itakura, Synthetic DNA and Medicine, 31 AM.
`J. HUM. GENET., 531–538 (1979) (“Riggs & Itakura”) (Ex. 1003).
`
`
`
`2
`
`

`

`IPR2017-00047
`Patent No. 6,331,415 B1
`
`
`References
`Bujard and Southern3
`
`Basis
`§ 103(a)
`
`Claims Challenged
`1, 2, 18, 20, and 33
`
`Mylan Pharmaceuticals, Inc. v. Genentech, Inc., Case IPR2016-00710, slip.
`op. at 15 (PTAB September 8, 2016) (Paper 13).
`Petitioner proposes an order in its Motion for Joinder in which the
`instant inter partes review is instituted only on the grounds for which inter
`partes review was instituted in the ’710 IPR. Mot. 12‒13. In view of the
`fact that the challenges presented by the instant Petition and the Petition in
`the ‘710 IPR are identical, and the evidence supporting the challenges is
`nearly so, see Mot. 1; Paper 10, 1 (noting that the Petition “raises the exact
`same art and arguments as in the petition in recently instituted IPR2016-
`00710”), we institute an inter partes review in this proceeding on the same
`grounds and for the same reasons as those on which we instituted the ’710
`IPR. We do not institute inter partes review on any other grounds or as to
`any additional claims.
`
`III. GRANT OF MOTION FOR JOINDER
`An inter partes review may be joined with another inter partes
`review, subject to the provisions of 35 U.S.C. § 315(c), which governs
`joinder of inter partes review proceedings:
`(c) Joinder.—If the Director institutes an inter partes review, the
`Director, in his or her discretion, may join as a party to that inter
`partes review any person who properly files a petition under
`section 311 that the Director, after receiving a preliminary
`
`3 P.J. Southern and P. Berg, Transformation of Mammalian Cells to
`Antibiotic Resistance with a Bacterial Gene Under Control of the SV40
`Early Region Promoter, 1 J. MOLECULAR AND APPLIED GENETICS 327–341
`(1982) (“Southern”) (Ex. 1004).
`
`
`
`3
`
`

`

`IPR2017-00047
`Patent No. 6,331,415 B1
`
`
`response under section 313 or the expiration of the time for filing
`such a response, determines warrants the institution of an inter
`partes review under section 314.
`As the moving party, Merck bears the burden of proving that it is
`entitled to the requested relief. 37 C.F.R. § 42.20(c). A motion for joinder
`should: (1) set forth the reasons joinder is appropriate; (2) identify any new
`grounds of unpatentability asserted in the petition; and (3) explain what
`impact (if any) joinder would have on the trial schedule for the existing
`review. See Frequently Asked Question H5, https://www.uspto.gov/patents-
`application-process/patent-trial-and-appeal-board/ptab-e2e-frequently-
`asked-questions (last visited December 7, 2016).
`The Petition in this proceeding has been accorded a filing date of
`October 11, 2016 (Paper 4), and the ’710 IPR was instituted on September 8,
`2016 (’710 IPR, Paper 13). Petitioner contends that the Motion for Joinder
`“is submitted within one month of September 8, 2016, the date on which the
`[’710 IPR] was instituted.” Mot. 2. The Petition, therefore, satisfies the
`joinder requirement of being filed within one month of our instituting a trial
`in the ’710 IPR. 37 C.F.R. § 42.122(b).4
`
`In its Motion for Joinder, Merck contends that the grounds asserted in
`the instant Petition are the same grounds of unpatentability asserted in the
`’710 IPR. Mot. 1, 5, 6‒7. Merck contends further that joinder is appropriate
`as it will promote efficient resolution of the challenges to the claims of the
`’710 patent. Id. at 1. Merck represents that joinder will not impact the
`schedule of the ’710 IPR, as it “agrees that the Scheduling Order issued in
`
`
`4 In that regard, we note that October 8, 2016, was a Saturday, and October
`10, 2016, was a Federal Holiday.
`
`
`
`4
`
`

`

`IPR2017-00047
`Patent No. 6,331,415 B1
`
`the [’710 IPR] will apply to the joined proceeding.” Id. at 9. Merck agrees
`also to consolidated filings and discovery. Id. at 10‒12. Moreover, Merck
`states that “Mylan consents to Merck’s request for joinder.” Id. at 1.
`Patent Owner states that it does “not object to Merck’s motion to join
`the present petition to IPR2016-00710, provided that, as a condition to
`joinder, Merck should not be permitted to proceed with its already-pending
`petition in IPR2016-01373.” Paper 10, 1. Inasmuch as we decline to
`institute trial in IPR2016-01373 under 35 U.S.C. § 325(d) concurrently with
`this decision, we understand Patent Owner to have no residual objection to
`Merck’s motion for joinder.
`
`As discussed above, joinder is discretionary. In the instant
`proceeding, we agree with Merck that joinder of the instant proceeding with
`the ’710 IPR would promote the efficient resolution of the proceedings.
`Merck has brought the same challenges as presented by the ’710 IPR, thus,
`the substantive issues in the ’710 IPR would not be unduly complicated by
`joining with the instant IPR. In particular, joinder merely introduces the
`same grounds presented originally in the ’710 IPR, where all of the prior art
`asserted in this Petition is of record. In addition, Merck agrees to be limited
`to the grounds on which trial was instituted in the ’710 IPR. Mot. 6‒9.
`Moreover, the instant proceeding was filed timely. Finally, Patent Owner
`will be able to address the challenges in a single proceeding, promoting
`efficiency.
`
`IV. ORDER
`
`In view of the foregoing, it is
`ORDERED that IPR2017-00047 is instituted and joined with
`IPR2016-00710;
`
`
`
`5
`
`

`

`IPR2017-00047
`Patent No. 6,331,415 B1
`
`
`FURTHER ORDERED that the grounds on which IPR2016-00710
`was instituted are unchanged and no other grounds are instituted in the
`joined proceeding;
`FURTHER ORDERED that the Scheduling Order entered in
`IPR2016-00710 shall govern the schedule of the joined proceedings;
`FURTHER ORDERED that, throughout the joined proceeding, Mylan
`or Merck will file papers, except for motions that do not involve the other
`party, as a single, consolidated filing; that the filing party (either Mylan or
`Merck) will identify each such filing as a consolidated filing;
`FURTHER ORDERED that, throughout the joined proceeding, Mylan
`and Merck will designate an attorney to conduct the cross-examination of
`any witness produced by Patent Owner, as well as the redirect of any witness
`produced by Mylan and Merck within the time provided by 37 C.F.R.
`§ 42.53, and Merck will not receive any cross-examination or redirect time
`separate from that of Mylan;
`FURTHER ORDERED that IPR2017-00047 is terminated under
`37 C.F.R. § 42.72, and all further filings in the joined proceedings are to be
`made in IPR2016-00710;
`FURTHER ORDERED that a copy of this Decision will be entered
`into the record of IPR2016-00710; and
`FURTHER ORDERED that the case caption in IPR2016-00710 shall
`be changed to reflect joinder with this proceeding in accordance with the
`attached example.
`
`
`
`
`
`
`6
`
`

`

`IPR2017-00047
`Patent No. 6,331,415 B1
`
`FOR PETITIONER MERCK SHARP & DOHME CORP.:
`
`Raymond N. Nimrod
`Matthew A. Traupman
`QUINN EMANUEL URQUHART & SULLIVAN, LLP
`raynimrod@quinnemanuel.com
`matthewtraupman@quinnemanuel.com
`
`Katherine A. Helm
`SIMPSON THACHER & BARTLETT LLP
`khelm@stblaw.com
`
`FOR PETITIONER MYLAN PHARMACEUTICALS INC.:
`
`Deanne Mazzochi
`Paul Molino
`RAKOCZY MOLINO MAZZOCHI SIWIK LLP
`dmazzochi@rmmslegal.com
`paul@rmmslegal.com
`
`FOR PATENT OWNER:
`
`David Cavanaugh
`Heather M. Petruzzi
`Owen Allen
`WILMER CUTLER PICKERING HALE AND DORR LLP
`David.cavanaugh@wilmerhale.com
`Heather.petruzzi@wilmerhale.com
`owen.allen@wilmerhale.com
`
`Adam R. Brausa
`DURIE TANGRI
`abrausa@durietangri.com
`
`Michael Fleming
`IRELL & MANELLA LLP
`mfleming@irell.com
`
`
`
`
`
`7
`
`

`

`IPR2017-00047
`Patent No. 6,331,415 B1
`
`Jeffrey P. Kushan
`SIDLEY AUSTIN LLP
`jkushan@sidley.com
`
`
`
`8
`
`

`

`
`
`
`
`
`
`
`
`Example Case Caption for Joined Proceeding
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________
`
`MYLAN PHARMACEUTICALS, INC., and
`MERCK SHARP & DOHME CORP.,
`Petitioners,
`v.
`
`GENENTECH, INC. AND CITY OF HOPE,
`Patent Owners.
`_______________
`
`Case IPR2016-007101
`Patent 6,331,415 B1
`_______________
`
`
`
`1 Case IPR2017-00047 has been joined with this proceeding.
`
`
`
`9
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket